Myosana Therapeutics
Building New Gene Therapies for Muscle and Heart Diseases
https://wefunder.com/myosana.therapeutics
Total raised on Wefunder: 549711
Total investors: 52
Quick facts
- Developing a gene therapy treatment for Duchenne muscular dystrophy (DMD).
- Designed to deliver full-length dystrophin to skeletal and cardiac muscle.
- Uses proprietary GLUT4-targeting antibodies to deliver DNA to muscle cells efficiently.
- Non-viral design allows repeat dosing, unlike most viral gene therapies.
- Investment from Parent Project Muscular Dystrophy, CureDuchenne Ventures, angel investor.
- Preclinical studies show significant dystrophin expression in DMD animal models.
- DMD treatment market projected to reach about $10B by 2030.
- A founding team with extensive experience in neuromuscular disease research and drug development.